Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 701 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenoma Clear all
Terminated Phase 1 Interventional

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

NCT04173338
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
Interventions
Cabozantinib, Pemetrexed
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)

NCT00525655
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Colorectal Cancer
Interventions
Web-Based Multimedia Intervention, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 28, 2026, 9:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Samples USOPTIVAL Study

NCT04792684
View directory record Official record
Conditions
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Interventions
Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Diagnostic Test
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
16
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times

NCT01802008
View directory record Official record
Conditions
Adenoma and/or Adenocarcinoma, Adenoma
Interventions
3-minute withdrawal time, 6-minute withdrawal time
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

NCT02812875
View directory record Official record
Conditions
Advanced Solid Tumors or Lymphomas
Interventions
CA-170
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 28, 2026, 9:20 AM EDT
Active, not recruiting Phase 2 Interventional

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

NCT03007030
View directory record Official record
Conditions
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

NCT01861301
View directory record Official record
Conditions
Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma, Stage III Pleural Mesothelioma, Stage IV Pleural Mesothelioma
Interventions
Laboratory Biomarker Analysis, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

Combination Gene Transfer and Chemotherapy

NCT01119664
View directory record Official record
Conditions
Mesothelioma
Interventions
SCH 721015
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Detection and Classification of Colon Polyps

NCT00825292
View directory record Official record
Conditions
Colon Polyps
Interventions
Polp removal and identification, colon polyp removal, ETMI colonoscope (ETMI scope is a FDA approved device)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Nintedanib (BIBF 1120) in Mesothelioma

NCT01907100
View directory record Official record
Conditions
Mesothelioma
Interventions
Nintedanib, Pemetrexed, Cisplatin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

NCT01056601
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Bortezomib, Panobinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated No phase listed Observational

Rapid Autopsy and Procurement of Cancer Tissue

NCT01851395
View directory record Official record
Conditions
Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers, Lung Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

NCT05041062
View directory record Official record
Conditions
Mesothelioma, Peritoneal Mesothelioma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 28, 2026, 9:20 AM EDT
Completed No phase listed Observational

Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis

NCT04761354
View directory record Official record
Conditions
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Primary Aldosteronism Due to Conn Adenoma
Interventions
Unilateral adrenalectomy
Procedure
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 28, 2026, 9:20 AM EDT
Recruiting Phase 2 Interventional

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Effect of Video Monitor Size on Adenoma Detection Rate

NCT01952418
View directory record Official record
Conditions
Colon Adenoma
Interventions
Monitor size
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 80 Years
Enrollment
1,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01824875
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
temozolomide, capecitabine
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
323
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 221 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AI_Colonoscopy_for_Fellows

NCT07661914
View directory record Official record
Conditions
AI-assisted Colonoscopy
Interventions
AI assisted colonoscopy, Conventional Colonoscopy
Device · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
View directory record Official record
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated No phase listed Observational

The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate.

NCT02538406
View directory record Official record
Conditions
Adenomatous Polyp of Colon
Interventions
Segmental withdrawal
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 28, 2026, 9:20 AM EDT
Recruiting Not applicable Interventional

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

NCT07126509
View directory record Official record
Conditions
Mesothelioma, Mesothelioma; Lung, Mesotheliomas Pleural, Mesothelioma Malignant Advanced, Mesothelioma, Malignant
Interventions
Partial Pleurectomy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 9:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

NCT03038308
View directory record Official record
Conditions
Hyperprolactinemia, Prolactinoma
Interventions
Ropinirole
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 28, 2026, 9:20 AM EDT
Terminated Not applicable Interventional Results available

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

NCT02672033
View directory record Official record
Conditions
Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 28, 2026, 9:20 AM EDT